Abstract
Studies show that PD-L1 receptor expression is an independent survival prognosticator in gastric cancer patients. However, sparce real-world data exist on PD-L1 expression and decisions regarding treatment in gastric cancer. The objectives of this study were to assess PD-L1 expression and use of immune checkpoint inhibitor (ICI) therapies among gastric cancer patients in the U.S.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have